Non-Opioid pain drug tested against standard analgesia for skin cancer surgery

NCT ID NCT07843134

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers compare suzetrigine, a non-opioid pain medicine, with scheduled acetaminophen plus ibuprofen for pain after skin cancer surgery on the head or neck. Adults having Mohs surgery or wide local excision receive one of the two treatments for 72 hours. The trial measures pain over the first 24 hours and tracks oxycodone use, side effects, and wound healing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
suzetrigine, a non-opioid pain medicine
What this could lead to
If suzetrigine controls pain as well as standard painkillers, it could offer a non-opioid option after skin cancer surgery and reduce reliance on oxycodone.
What could go wrong
The trial may show suzetrigine does not match standard analgesia, and it is limited to a specific surgery type and 72 hours of treatment. Side effects, bleeding, and wound-healing problems are monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 230 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2027

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Biopsy-proven cutaneous malignancy of the head or neck, including melanoma, melanoma in situ, cutaneous squamous cell carcinoma, or basal cell carcinoma, or a biopsy-confirmed precursor lesion to skin cancer requiring excision * Planned treatment by Mohs micrographic surgery or wide local excision * Surgical defect requiring intermediate layered closure, complex closure, adjacent tissue transfer, or full-thickness skin graft * Able to take oral medications * Access to an electronic diary device, or willingness to use a paper backup * Able to provide written informed consent, with English, Hmong, or Somali language materials and interpreter support available Exclusion Criteria: * Contraindication to ibuprofen, including active peptic ulcer disease, history of gastrointestinal bleeding, estimated glomerular filtration rate below 30 mL/min/1.73 m², or NSAID hypersensitivity * Moderate or severe hepatic impairment, defined as Child-Pugh Class B or C * Chronic heavy alcohol use * Known hypersensitivity to acetaminophen * Known hypersensitivity to opioids * Severe untreated obstructive sleep apnea or other respiratory compromise that would make a short course of breakthrough oxycodone unsafe * Concurrent use of a benzodiazepine or other sedative-hypnotic * Concurrent use of a strong or moderate CYP3A inhibitor, or a strong or moderate CYP3A inducer * Regular opioid use in the prior 30 days, meaning opioid use on most days or any standing opioid prescription * Body weight below 50 kg * Prior major bleeding on a nonsteroidal anti-inflammatory drug, or an active bleeding disorder * Pregnancy or breastfeeding * Prior adverse reaction to suzetrigine * Cognitive impairment precluding completion of patient-reported outcomes * Participation in another interventional trial within 30 days * Children * Fetuses * Neonates * Prisoners * Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent * Employees of the researcher * Students of the researcher * Individuals approached in emergency or acutely stressful settings

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • M Health Fairview Clinic - Maple Grove

    Maple Grove, Minnesota, 55369, United States

  • M Health Fairview Clinic - Wyoming

    Wyoming, Minnesota, 55092, United States

  • M Health Fairview Clinics and Surgery Center

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.